Skip to main content
SpringerLink
Log in

The impact of S-1 for the patient with lymph nodal metastasis biliary tract cancer as adjuvant chemotherapy: a multicenter database analysis

  • Original Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Introduction

Although adjuvant chemotherapy is expected to improve the prognosis for patients with biliary tract cancer after curative resection, there is limited evidence regarding the efficacy and prognostic factors of adjuvant chemotherapy. We investigated the effective subgroups for whom adjuvant chemotherapy with S-1 in biliary tract cancer patients.

Methods

413 patients who underwent curative resection for biliary tract cancer at our four affiliated hospitals between 2009 and 2019 were included in this study. The association of adjuvant chemotherapy with long-term outcomes in overall and patient subgroups were investigated by univariate and multivariate analyses.

Results

Among overall patients, adjuvant chemotherapy with S-1 did not improve disease free survival (p = 0.29) and overall survival (p = 0.83). In the subgroup analysis, adjuvant chemotherapy with S-1 improved both disease-free and overall survival in patients with lymph node metastasis, advanced Stage (III and IV), and microscopic residual tumor. In 135 patients with lymph node metastasis, adjuvant chemotherapy with S-1 was given in 67 patients (50%). In the patients with lymph node metastasis, preoperative bile duct drainage (p = 0.01) and adjuvant chemotherapy (p = 0.04) were independent and significant predictors of disease-free survival, while preoperative bile duct drainage (p = 0.03), tumor differentiation (p = 0.03), and adjuvant chemotherapy (p = 0.03) were independent and significant predictors of overall survival.

Conclusion

After resection of biliary tract cancer, adjuvant chemotherapy with S-1 appears to benefit those who had lymph node metastasis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Vital Statistics Japan (2020) Ministry of Health, Labour and Welfare

  2. Banales JM, Marin JJG, Lamarca A et al (2020) Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol 17:557–588

    Article  Google Scholar 

  3. Horgan AM, Amir E, Walter T et al (2012) Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. J Clin Oncol 30:1934–1940

    Article  Google Scholar 

  4. Nara S, Esaki M, Ban D et al (2020) Adjuvant and neoadjuvant therapy for biliary tract cancer: a review of clinical trials. Jpn J Clin Oncol 50:1353–1363

    Article  Google Scholar 

  5. Siegel RL, Miller KD, Jemal A (2020) Cancer statistics, 2020. CA Cancer J Clin 70:7–30

    Article  Google Scholar 

  6. Shroff RT, Kennedy EB, Bachini M et al (2019) Adjuvant therapy for resected biliary tract cancer: ASCO Clinical Practice Guideline. J Clin Oncol 37:1015–1027

    Article  Google Scholar 

  7. Kim HS, Jang JY, Yoon YS et al (2020) Does adjuvant treatment improve prognosis after curative resection of ampulla of Vater carcinoma? A multicenter retrospective study. J Hepatobiliary Pancreat Sci 27:721–730

    Article  Google Scholar 

  8. Hester C, Nassour I, Adams-Huet B et al (2018) Improved survival in surgically resected distal cholangiocarcinoma treated with adjuvant therapy: a propensity score matched analysis. J Gastrointest Surg 22:2080–2087

    Article  Google Scholar 

  9. Ebata T, Hirano S, Konishi M et al (2018) Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer. Br J Surg 105:192–202

    Article  CAS  Google Scholar 

  10. Edeline J, Benabdelghani M, Bertaut A et al (2019) Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study. J Clin Oncol 37:658–667

    Article  CAS  Google Scholar 

  11. Primrose JN, Fox RP, Palmer DH et al (2019) Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol 20:663–673

    Article  CAS  Google Scholar 

  12. Ishihara S, Horiguchi A, Miyakawa S et al (2016) Biliary tract cancer registry in Japan from 2008 to 2013. J Hepatobiliary Pancreat Sci 23:149–157

    Article  Google Scholar 

  13. Nagino M, Ebata T, Yokoyama Y et al (2013) Evolution of surgical treatment for perihilar cholangiocarcinoma: a single-center 34-year review of 574 consecutive resections. Ann Surg 258:129–140

    Article  Google Scholar 

  14. Sakamoto Y, Kosuge T, Shimada K et al (2005) Prognostic factors of surgical resection in middle and distal bile duct cancer: an analysis of 55 patients concerning the significance of ductal and radial margins. Surgery 137:396–402

    Article  Google Scholar 

  15. Furuse J, Okusaka T, Boku N et al (2008) S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study. Cancer Chemother Pharmacol 62:849–855

    Article  CAS  Google Scholar 

  16. Suzuki E, Ikeda M, Okusaka T et al (2013) A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer. Cancer Chemother Pharmacol 71:1141–1146

    Article  CAS  Google Scholar 

  17. Sasaki T, Takeda T, Okamoto T et al (2021) Chemotherapy for biliary tract cancer in 2021. J Clin Med 10:3108

    Article  CAS  Google Scholar 

  18. Fujiwara Y, Haruki K, Hamura R et al (2020) A novel prognostic score combining preoperative biliary drainage and inflammatory status for patients with periampullary cancers. J Gastrointest Surg 24:813–822

    Article  Google Scholar 

  19. Uemura K, Murakami Y, Satoi S et al (2015) Impact of preoperative biliary drainage on long-term survival in resected pancreatic ductal adenocarcinoma: a multicenter observational study. Ann Surg Oncol 22(Suppl 3):S1238-1246

    Article  Google Scholar 

  20. Verlingue L, Hollebecque A, Boige V et al (2017) Matching genomic molecular aberrations with molecular targeted agents: are biliary tract cancers an ideal playground? Eur J Cancer 81:161–173

    Article  CAS  Google Scholar 

  21. Nakamura H, Arai Y, Totoki Y et al (2015) Genomic spectra of biliary tract cancer. Nat Genet 47:1003–1010

    Article  CAS  Google Scholar 

Download references

Funding

This work was supported by JSPS KAKENHI Grant Number JP21K08805.

Author information

Authors and Affiliations

  1. Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The Jikei University School of Medicine, 3-25-8, Nishi-Shinbashi, Minato-ku, Tokyo, 105-8461, Japan

    Ryoga Hamura, Koichiro Haruki, Tomohiko Taniai, Mitsuru Yanagaki, Yoshihiro Shirai, Kenei Furukawa, Tadashi Uwagawa & Toru Ikegami

  2. Department of Surgery, The Jikei University Katsushika Medical Center, Tokyo, Japan

    Teruyuki Usuba

  3. Department of Surgery, The Jikei University Kashiwa Hospital, Chiba, Japan

    Shuichi Fujioka

  4. Department of Surgery, The Jikei University Daisan Hospital, Tokyo, Japan

    Tomoyoshi Okamoto

  5. Department of Surgery, Kawaguchi Municipal Medical Center, Saitama, Japan

    Yukio Nakabayashi

Authors
  1. Ryoga Hamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Koichiro Haruki
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tomohiko Taniai
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mitsuru Yanagaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yoshihiro Shirai
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kenei Furukawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Teruyuki Usuba
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Shuichi Fujioka
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Tomoyoshi Okamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Yukio Nakabayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Tadashi Uwagawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Toru Ikegami
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Each of the author have participated sufficiently in the work to take public responsibility for appropriate portions of the content.

Corresponding author

Correspondence to Koichiro Haruki.

Ethics declarations

Conflict of interest

The authors declare that they have no conflicts of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 28 kb)

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hamura, R., Haruki, K., Taniai, T. et al. The impact of S-1 for the patient with lymph nodal metastasis biliary tract cancer as adjuvant chemotherapy: a multicenter database analysis. Int J Clin Oncol 27, 1188–1195 (2022). https://doi.org/10.1007/s10147-022-02165-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-022-02165-1

Keywords

Search

Navigation